Guaranteed Leads, Pay Per Lead and Commission Offers: Why Medtech Companies Should Say No

Why a guaranteed lead offer is tempting, and what to check first

The offer usually arrives as a relief. You have been burned by a program that spent money and produced nothing you could point to, and here is a vendor willing to take the risk: a set number of qualified leads every month, or no fee until you sell something. The real question is not whether the vendor is confident. It is what you are actually buying, and who decides whether you got it.

This article is fair to the business model. Paying per lead is normal in some markets, and there are honest vendors who sell that way. It is a poor fit for most medical device and clinical products, for reasons that have to do with how those products are bought.

What a guaranteed lead offer actually buys

A guarantee is only as good as the definition in the contract. A promise of a set number of qualified leads means that number of records that meet whatever the contract says a qualified lead is. If the definition is "a completed form with a valid email and phone number," that is what you are guaranteed.

Before you compare any guarantee, get written answers to five questions.

1. How is a lead defined? Role, specialty, site type, geography, and the action they took.
2. Where do the leads come from? Your own ads and pages, the vendor's websites, purchased lists, co-registration forms, or forms that offer a gift card or other reward for filling them in.
3. Are they exclusive? Or is the same contact also sold to your competitors?
4. How do you return a bad lead? Who decides it is bad, and how long do you have?
5. What happens if the guarantee is missed? A refund, a credit against future fees, or just more leads and a longer term.

If the answers are vague, the guarantee is too.

The incentive a per-lead price creates

When you pay per lead, the vendor makes the most money by producing leads that meet the definition at the lowest cost. That is not dishonest. It is what the contract pays for. But in medtech it pushes in the wrong direction.

The people you need are a small group: clinicians in one or two specialties, the owners of practices that could buy, the people who run value analysis and purchasing. They are expensive to reach and slow to fill in forms. Students, job seekers, patients and vendors are cheap to reach and quick to fill in forms. A per-lead contract rewards reaching the second group. Guarantees also carry a price for the vendor's risk, so the fee per lead includes a margin to cover the months when the count falls short.

Price per lead can also hide what you are paying for real buyers. Here is an illustrative example with made-up numbers.

Offer A looks cheaper on the proposal and costs more per lead that matters. You can only see this if you count qualified leads separately from contacts. If you do not have lead stages yet, start with what counts as a lead when the buyer is a physician.

When pay per lead can be a fair deal

There are cases where paying per lead or per action works for both sides.

• The lead can be defined and checked exactly. A booked appointment, a verified license number, a specific request with a named site.
• You control the source. The leads come from your own ads and pages, so you know who was reached and how.
• The leads are exclusive to you and there is a clear return policy.
• The sale is short and simple, so a lead turns into revenue quickly enough for both sides to see the result.

Online directories and booking platforms often charge per click or per booking, and that model is not automatically unlawful. In OIG Advisory Opinion 23-04, issued July 6, 2023, the HHS Office of Inspector General said one online health care directory's per-booking and per-click fees could be prohibited remuneration if the required intent were present, but that it would not impose sanctions, given the safeguards that directory had described. The opinion applies only to that requester and those facts, but it shows how much depends on the details. Most device sales to hospitals and practices do not meet the conditions above.

Why commission on sales does not fit a medical device sale

A commission offer sounds like the fairest deal of all: pay only when you sell. In practice it creates problems that are hard to fix in a contract.

• The marketer does not control the sale. Price, rep follow-up, value analysis approval, contracting and purchasing are all outside the marketer's hands.
• The lag is long. A clinical sale can take a quarter or more from first contact to first order. The marketer carries costs for months, then prices that risk into the commission.
• Nobody can agree what caused the sale. Was it the ad, the rep, the congress, the colleague who recommended you? Every commission payment becomes a negotiation.
• It needs your sales data. To be paid fairly, the marketer needs to see and audit your orders and customer list.
• It turns the marketer into a sales rep. A commission-paid partner is really a distributor or independent rep, which is a different relationship with different contracts and, in healthcare, different compliance review.

If you want a performance element, there is a simpler way to build one. Pay a flat fee for the work, and add a small bonus with a cap, tied to one event you can verify yourself, such as a booked evaluation. Only do it once the tracking for that event is working, and have counsel review it if your product is paid for by federal health programs.

The Anti-Kickback question to take to your counsel

This section is not legal advice. It explains why you should ask.

The federal Anti-Kickback Statute, 42 U.S.C. 1320a-7b(b), is, in the words of the HHS Office of Inspector General, "a criminal law that prohibits the knowing and willful payment of 'remuneration' to induce or reward patient referrals or the generation of business involving any item or service payable by the Federal health care programs." OIG notes that it applies to both sides: "those who offer or pay remuneration" and "those who solicit or receive remuneration."

Three points from primary sources are worth knowing before you talk to counsel.

1. Marketing can be covered. In OIG Advisory Opinion 98-4, dated April 15, 1998, OIG wrote: "Percentage compensation arrangements for marketing services may implicate the anti-kickback statute."
2. The safe harbor for service contracts excludes volume-based pay. The personal services and management contracts safe harbor, 42 CFR 1001.952(d)(1)(iv), requires that the method for setting compensation be "set in advance," "consistent with fair market value in arm's-length transactions," and "not determined in a manner that takes into account the volume or value of any referrals or business otherwise generated between the parties" for federally reimbursed business. Pay calculated per sale or per referral in that business is tied to volume by design, so it does not fit this safe harbor.
3. Falling outside a safe harbor is not automatically illegal. OIG said so in Advisory Opinion 98-4, and it looks at each arrangement on its facts, as Advisory Opinion 23-04 above shows.

So if your product or service is paid for, in whole or in part, by Medicare, Medicaid or other federal health programs, show any per-lead, per-referral, per-sale or percentage marketing offer to your healthcare counsel before you sign it. Paying anyone per referral or per introduction to clinicians is the arrangement to be most careful with. For the wider picture, see the Anti-Kickback Statute guide for device marketing.

What to ask for instead: a paid audit or pilot with written measures

The honest alternative to a guarantee is a short, paid first phase with measures agreed in writing before it starts. You take less risk because the commitment is small, not because someone promised an outcome.

Ask for these things in the proposal.

1. A fixed scope and a fixed length, usually 30 to 90 days, with a written price.
2. Something you can see at the end of each phase. For example: working tracking and a written findings report in month one, live campaigns in month two, first optimization and a cost report in month three.
3. Tracking checked first. Every conversion should fire on the real business action, such as a sample request or a booked evaluation, not a page view.
4. Lead stages agreed with your sales team, and a monthly report of counts, movement between stages and cost per stage.
5. A decision date. On that date you decide, with the numbers in front of you, whether to continue, change or stop.
6. You own everything. Ad accounts, analytics, pages, data and creative are in your name, and ad spend is paid by you directly to the platforms.

For what each phase should include, see what the first 90 days with a new marketing partner should deliver. A short first phase is also the fastest way to find out whether a marketing partner knows your market. See red flags when hiring a healthcare marketing agency and how to measure your agency's return.

What Buzzbox Media promises, and what it does not

Buzzbox Media does not guarantee leads, rankings or return on spend. Nobody can honestly promise how many clinicians will act on a campaign before it has run.

What Buzzbox Media commits to is the work described in a written scope, tracking that counts the real business action, and a monthly report that shows what you spent and what it produced at each lead stage. That gives you what a guarantee claims to give you: a clear point at which to decide whether the money is working.